Endothelial cells impart thromboresistance to the blood vessel wall. As modulators of fibrinolytic activity, these cells synthesize and secrete tissue plasminogen activator (t-PA) as well as its physiologic inhibitor, plasminogen activator inhibitor-i. In addition, endothelial cells support membrane-associated assembly of plasminogen and tissue plasminogen activator. Recently, an M, -40,000 protein expressed on endothelial cells has been shown to interact noncompetitively through disparate mechanisms with both t-PA and plasminogen, suggesting trimolecular assembly of enzyme, substrate, and receptor (Hajjar, K. A. 1991. J. BioL. Chem. 266:21962-21970). In the present study, treatment of cultured endothelial cells with DL-homocysteine was specifically associated with a selective reduction in cellular binding sites for t-PA. This 65% decrease in binding was associated with a 60% decrease in cell-associated t-PA activity. No change in affinity for t-PA or plasminogen or in the maximal number of binding sites for plasminogen was observed. Matrix-associated t-PA binding sites were not affected. These data suggest a new mechanism whereby homocysteine may perturb endothelial cell function, thus promoting a prothrombotic state at the surface ofthe blood vessel wall. (J.
Introduction
Homocysteine is a normal metabolite which accumulates intracellularly and in plasma in certain inborn errors oftranssulfuration. In homozygous cystathionine-fl-synthase deficiency, the commonest form of homocystinuria, accumulation of homocysteine is accompanied by developmental delay, osteoporosis, and ectopia lentis ( 1). In addition, as many as 50% of patients with this disorder experience a major thromboembolic episode by 30 yr of age, and vascular occlusion is a primary factor in 66% of all fatal events (2) . Recent evidence suggests, furthermore, that heterozygous homocysteinemia represents a significant independent risk factor for premature atherosclerotic vascular disease involving peripheral, cerebral, and coronary arteries (3) (4) (5) (6) (7) . Although the mechanism by which homocysteine may promote atherothrombotic disease is not established, several recent reports have demonstrated a potential role for homocysteine in endothelial cell dysfunction in vitro. Reported alterations in the thromboregulatory properties of endothelial cells upon exposure to homocysteine (HC)' include induction ofa protease activator ofcoagulation Factor V (8) , induction of an inhibitor of protein C activation (9) , aberrant secretion of thrombomodulin (10) , and inhibition of thrombomodulin cofactor activity ( 11) .
Endothelial cells line the vasculature and function to maintain the fluidity of blood ( 12) . Plasmin generation in vitro is supported by cell surface assembly of its circulating precursor, plasminogen, and its endothelial cell-derived activator, tissue plasminogen activator (t-PA) (13) . Recent evidence demonstrates that both the plasmin-forming enzyme, t-PA (Kd 10-20 nM), and its substrate, plasminogen (Kd 120-300 nM), interact noncompetitively with distinct domains associated with a common cell surface binding protein (t-PA/plasminogen receptor) synthesized by the endothelial cell ( 14) . In a purified system, and on the surface of cultured cells, this M, 40, 000 protein enhances the catalytic activity of t-PA ( 14-16) and protects it from its physiologic inhibitor, plasminogen activator inhibitor-I (PAI-1) ( 14) . Upon binding to the endothelial cell, amino-terminal glutamic acid plasminogen is partially converted to a higher affinity, cleaved derivative (amino-terminal lysine plasminogen; Lys-PLG) through the action of a serine protease possessing plasmin-like specificity ( 17) . Lys-PLG is activated by t-PA and urokinase approximately 10 to 20 times more efficiently than Glu-PLG ( 18, 19) , thus providing for catalytic amplification at the cell surface.
Interactions ofplasminogen and tissue plasminogen activator with endothelial cells appear to be independently regulated.
Plasminogen binding to the endothelial cell or to its purified M, 40 ,000 receptor appears to involve "kringle"-associated lysine binding sites since it can be blocked by basic amino acids such as E-aminocaproic acid, tranexamic acid, lysine, and arginine ( 14, 20) . t-PA binding, on the other hand, is relatively insensitive to these agents, indicating that lysine binding sites are not required for the interaction ( 14, 15) . Binding of Lys-PLG to endothelial cells, furthermore, is also inhibited in the presence of molar excesses of lipoprotein (a) (21-23), an atherogenesis-associated low density lipoprotein whose apoprotein (a) contains multiple, tandemly repeated units of plasminogen-like kringle IV (24, 25) . These structures appear to allow Lp(a) to compete with Lys-PLG, but not t-PA, for binding to the Mr 40,000 receptor ( 14) . Factors ( 14) as described (26) .
Cell culture. Endothelial cells (passages 1-5), propagated as previously described ( 14, 16, 19) , were seeded in 24-well cluster dishes and reached confluency within 2-3 d. On day 5 or 6, 50% of postculture medium was replaced by complete medium containing DL-homocysteine or related compounds.
Cell treatment with sulfur-containing compounds. Twice final concentrations of DL-homocysteine, L-cysteine, L-methionine, and glutathione were prepared in complete culture medium. L-homocystine and L-cystine were dissolved first in 1 N HCl, added dropwise to an equal volume of 0.5 M NaHCO3, and then diluted into 9 vol complete culture medium to achieve twice final concentration. The resulting media were pH-adjusted to 7.4 as necessary with 0.5 M NaHCO3, sterile filtered, and added to wells from which 50% of postculture medium had been removed. Endothelial cells (EC) were cultured further for up to 96 h. Cell viability. Cell viability was assessed essentially as described by Rodgers and Kane (8) . Confluent endothelial cells were loaded with Na25"CrO4 ( 1 uCi/ml complete culture medium, 18 h), washed three times with Hepes-buffered saline (HBS) (11 mM Hepes, 137 mM NaCl, 4 Cell counts. Cells were enumerated in a hemocytometer after detachment with 0.02% type I collagenase in Hepes-buffered saline containing 0.01% EDTA and 0.25% BSA at 37°C.
Radioligand binding studies. t-PA and Lys-PLG were radiolabeled as previously described ( 15, 20) . Murine antireceptor IgG was labeled as described (20) . At specified times, control or HC-treated monolayers were equilibrated to 4°C, washed twice with ice cold IB( 5 ) (HBS containing 3 mM CaCl2, 1 mM MgCl2, and BSA 5 mg/ml), once with IB(5 )/ 10 mM e-aminocaproic acid, and twice more with IB( 5). 1251-t-PA or '25I-Lys-PLG were added, and cells incubated (40C, 30 min) before sampling free radioactivity. Cell monolayers were washed five times rapidly with IB(5), and then solubilized (580C, 60 min) in 1% SDS, 0.5 M NaOH, 0.01 M EDTA, before sampling bound radioactivity.
Ligand blotting. Ligand blotting was carried out as previously described (14, 16) . Blots were imaged on a UMAX MaxColor UC630 and analyzed using the NIH Image 1.41 program.
Membrane preparation. Endothelial cell plasma membraneenriched fractions were prepared as previously described ( 16) .
Plasminogen activator activity studies. Confluent endothelial cells
were treated with complete medium with or without 5 mM homocysteine, and incubated for 24 h. After equilibration to 4VC, cells were washed three times with ice cold IB(2) (Hepes-buffered saline containing 3 mM CaCl2, 1 mM MgCl2, and BSA 2 mg/ml), and then incubated at 4VC with IB (2) Addition of catalase, superoxide dismutase, or both at the time oftreatment with HC, had no effect on the observed decrement in specific t-PA binding, ruling out toxicity related to generation ofoxidizing species (Fig. 2 B) (27) (Fig. 2 C) . Recovery of '251-t-PA binding capacity to within 15% ofuntreated cells was observed at 72-96 h, possibly reflecting expression ofnewly synthesized receptors. The observation of a 20-h lag period preceding the maximal HC effect suggested that one or more processing events might be required before an effect on t-PA binding could be appreciated at the cell surface. Among cells pretreated with HC analogues (L-homocystine, L-cysteine, L-cystine, L-methionine, or glutathione), binding of '25I-t-PA did not differ by > 15% when compared with that of untreated cells (Fig. 2 D) . This result suggested that modulation of 1251I-t-PA binding was specific to homocysteine, and not simply a consequence of excess reducing potential in the extracellular environment. In addition, the effect of HC on '251-t-PA binding was completely abrogated by coincubation of cells with excess L-cysteine, a competitive inhibitor of HC uptake by endothelial cells (Fig. 2 E) (28) . Halfmaximal restoration of 1251-t-PA binding to HC-treated cells (5 mM) was observed upon coincubation with roughly equimolar doses of L-cysteine ( -4.8 mM). Thus, cellular uptake of HC appeared to be necessary for modulation of 1251I-t-PA binding.
Previous studies have identified two discrete, saturable binding sites for t-PA associated with cultured EC monolayers (15, 29) . These two classes can be resolved by Scatchard analysis of binding isotherms (15) . A high affinity site (Kd 29 pM, maxi- mal binding capacity [Bm.,] 3,700 sites per cell), representing the physiologic t-PA inhibitor, PAI-M, is located primarily in extracellular matrix (29, 30) . A lower affinity site (Kd 18 nM, Bm',, 815,000 sites per cell), representing an Mr 40,000 membrane protein, preserves catalytic activity (14) (15) (16) . To determine which binding site(s) might be targeted by HC, isotherms depicting the dose-dependent interaction of a range ofconcentrations (0.05-40 nM) of '251-t-PA with HC-treated or untreated confluent EC monolayers were developed (Fig. 3 A) . At 25-40 nM input doses of '251-t-PA, cells pretreated with HC displayed significantly dampened binding capacity for the labeled ligand. Scatchard transformation ofthese data (Fig. 3 A The ligand binding capacity of the M, 40,000 receptor, extracted from membrane preparations from control cells and cells pretreated with HC, was also evaluated by ligand blotting (Fig. 3 B) . Although the Mr 40,000 receptor from normal cells bound t-PA efficiently, as previously reported ( 14, 16) , the same protein from HC-treated cells showed a 65% loss ofreceptor interaction with t-PA by image analysis of ligand blots. Urokinase, a negative control ( 14) , did not bind to the Mr 40,000 protein in either case. Binding of both Lys-PLG and apo(a) to the t-PA/plasminogen receptor remained intact upon pretreatment of endothelial cells with HC. These data demonstrate that t-PA and plasminogen interact with EC through disparate mechanisms, only the former of which is sensitive to HC. Active site blockade of t-PA with diisopropylfluorophosphate had no effect on the observed decrease in specific binding to EC (Fig. 3 C) . This result provided further evidence that HC targeted a binding site other than PAl-1, a protein which lacks cysteine residues (31). Interestingly, a previous preliminary report suggests that HC has no effect on PAI-1 secretion while significantly hindering cellular processing of the integral membrane protein, thrombomodulin (32) .
Our previous studies have demonstrated that the endothelial cell membrane receptor for t-PA preserves its catalytic activity ( 14-16), whereas PAI-1 rapidly inactivates this protease (31, 32) . To further distinguish between PAI-1 and the EC membrane receptor, HC-treated endothelial cell monolayers were tested for the ability to support t-PA activity. Upon exposure of t-PA to HC-treated EC, hydrolysis of the fluorogenic t-PA substrate AFC-56 was reduced to 39% of that associated with control cells (0.00443±0.00127 vs 0.01 140±0.00114 relative fluorescence units/min, mean±SE, n = 5). This finding reflected a significant loss of t-PA catalytic activity at the surface of HC-treated cells. This result could not be explained by enhanced binding of t-PA to PAI-1 since binding of active site blocked t-PA was unchanged by HC (Fig. 3 C) . The observed decrease in cell associated plasminogen activating activity, thus, further localized the HC effect to the membrane-associated t-PA binding site.
Finally, purified receptor protein was treated with carboxy- Figure 3 . Effect of DL-homocysteine on '25I-t-PA binding to its endothelial cell membrane receptor. (A) Binding isotherms. Confluent EC, preincubated with HC (5 mM, 18 h) or complete medium, were washed and exposed to a range ofconcentrations of '25I-t-PA (sp act 433,000 cpm/pmol). Specific binding was quantified as described ( 14) . (Inset) Scatchard analysis. Data depicted in A were linearly transformed using the Ligand program (39) . (B) Ligand blot. Detergent extracts of plasma membrane fractions from EC treated with or without HC (1 mM, 18 h) were prepared, resolved by SDS-PAGE, and blotted with t-PA (10 jig/ml), u-PA (10 ,g/ml), Lys-PLG (1.0 tg/ml), or apolipoprotein(a) (1.0 gg/ml) as previously described ( 14, 16 (Fig. 2 B) , and was relatively specific for HC since related analogues such as cysteine, methionine, glutathione, homocystine, or cystine did not affect binding by > 15% (Fig. 2 D) . That cellular entry of HC was involved in modulation of t-PA binding is supported by the shape change observed in HCtreated endothelial cells suggesting cytoskeletal rearrangement (Fig. 1) , the time delay of several hours needed to achieve the full HC effect (Fig. 2 C) , blockade ofthe HC effect by a competitive inhibitor of its endothelial cell uptake (Fig. 2 E) , and the lack ofeffect on binding when the purified receptor was treated with HC. (Fig. 3 A; Table I ). Ligand blots of EC membrane extracts revealed 65% impairment of t-PA binding to the M, 40,000 receptor (Fig. 3 B) . In addition, HC treatment of EC was associated with a commensurate loss oft-PA catalytic activity at the cell surface. Finally, covalent blockade of the active site of t-PA did not alter the susceptibility of binding to HC, indicating that HC affected a binding compartment which was active site independent (Fig. 3 C) .
Fasting plasma levels of homocysteine in patients affected with homocystinuria range from 0.03 to 0.24 mM (33) (34) (35) . In the present report, as in other published studies using normal EC (8) (9) (10) (11) , relatively high doses of HC (. 1 More recent in vitro studies have focused on homocysteine-asct of carboxypeptidase B on '251I-Lys-PLG and 1251-t-PA sociated alterations in the thromboregulatory properties of the rified receptor protein. Solid phase binding studies were endothelial cell which were not accompanied by cell lysis (8-previously described ( 14) . Wells coated with purified 11 ). Our results are most consistent with the latter hypothesis, -in (10 ,g/ml) were washed three times, treated with but the extent to which endothelial cell dysfunction may conlase B (0-250 U/ml, 30 min, 37°C), and washed again tribute to vascular occlusion will await clinical study.
three times. Radiolabeled ligands were added (120 min, 37°G), and bound and unbound radioactivity estimated (14) . the effects of HC when compared to EC from individuals heterozygous for homocystinuria (36) . The high threshold noted for normal EC in vitro most likely reflects the need to transport externally presented HC to the intracellular space. In the normal cell, furthermore, the cystathionine f3-synthase pathway, which catalyzes the condensation of HC and serine to form the thioether cystathionine, would need to be overcome. This may explain why, in our system, preincubation with HC resulted in a less than complete loss oft-PA binding and activity at the cell surface, and why we observed recovery of binding at 72-96 h.
Recovery may also be due to inactivation of HC secondary to formation of mixed disulfides with serum proteins (5) . The mechanism by which HC selectively disables the t-PA binding domain of its membrane receptor is currently under investigation. Although EC are known to maintain homocys- 
